Farallon Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Farallon Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-14,645	Closed	-$2.49M	–	78
2015 Q3	$2.49M	Buy	14,645 +4,344	+42%	+$1.57M	0.03%	74
2015 Q2	$6.51M	Buy	+10,301	New	+$5.47M	0.09%	77
2014 Q3	–	Sell	-3,190	Closed	-$4.37M	–	97
2014 Q2	$4.37M	Sell	3,190 -4,429	-58%	-$5.14M	0.06%	78
2014 Q1	$10.6M	Buy	7,619 +2,619	+52%	+$3.05M	0.21%	60
2013 Q4	$4.98M	Buy	5,000 +1,595	+47%	+$1.65M	0.1%	65
2013 Q3	$3.55M	Buy	3,405 +1,143	+51%	+$1.22M	0.07%	69
2013 Q2	$2.48M	Buy	+2,262	New	+$2.52M	0.05%	78

Other funds holding VIRX

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

FWM

Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Farallon Capital Management's VIRX Position: Q4 2015 in Review

Farallon Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2015, closing a stake of 14,645 shares — an estimated $2.49M sold.

Farallon Capital Management first reported a position in VIRX in Q2 2013 and held it in 7 quarters. The position peaked at $10.6M in Q1 2014. 55 funds tracked by Wall St. Rank hold VIRX as of Q4 2015.

Farallon Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
Farallon Capital Management sold 14,645 Viracta Therapeutics, Inc. Common Stock shares in Q4 2015, an estimated $2.49M.
Farallon Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 7 quarters.
Farallon Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $10.6M in Q1 2014.
55 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2015.

Based on Farallon Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.